In conclusion, IFN-γ signaling plays an anti-tumor role during ICI therapy, which is involved in the processes of DCs maturity and CD8 T cell activation, both of which critical steps for anti-tumor immune responses. The gene discussed is CD8A; the disease is neoplasm.